Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]

  • In development
  • GID-TA11733
  • Expected publication date: 
To appraise the clinical and cost effectiveness of OAV101 IT within its marketing authorisation for treating spinal muscular atrophy ID6556